Biodesix Stock Investor Sentiment

BDSX Stock  USD 1.33  0.05  3.91%   
Slightly above 53% of Biodesix's investor base is interested to short. The analysis of the overall investor sentiment regarding Biodesix suggests that many traders are impartial. Biodesix's investing sentiment can be driven by a variety of factors including economic data, Biodesix's earnings reports, geopolitical events, and overall market trends.
  

Biodesix Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Biodesix can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
23 hours ago at www.macroaxis.com         
Disposition of 2781 shares by Scott Hutton of Biodesix at 1.601 subject to Rule 16b-3
Macroaxis News
2 days ago at finance.yahoo.com         
Insider Buys Additional US234k In Biodesix Stock
Yahoo News
3 days ago at investing.com         
Biodesix director Kennedy Lawrence T. Jr buys 40,561 in stock
Investing News at Macroaxis
3 days ago at investing.com         
Acquisition by Kennedy Lawrence T. Jr of 35000 shares of Biodesix at 1.1589 subject to Rule 16b-3
Investing News at Macroaxis
3 days ago at investing.com         
Biodesix director Jack Schuler buys 122,840 in stock
Investing News at Macroaxis
few days ago at investing.com         
Acquisition by Kennedy Lawrence T. Jr of 35000 shares of Biodesix at 1.1589 subject to Rule 16b-3
Investing News at Macroaxis
few days ago at simplywall.st         
With A 26 percent Price Drop For Biodesix, Inc. Youll Still Get What You Pay For
Simply Wall St News at Macroaxis
few days ago at investing.com         
Biodesix Inc director Jack Schuler buys 234,000 in shares
Investing News at Macroaxis
few days ago at zacks.com         
Acquisition by Schuler Jack W of 200000 shares of Biodesix at 1.17 subject to Rule 16b-3
zacks News
few days ago at zacks.com         
Biodesix Loses -22.98 percent in 4 Weeks, Heres Why a Trend Reversal May be Around the Corner
zacks News
six days ago at www.macroaxis.com         
Disposition of tradable shares by Gary Pestano of Biodesix subject to Rule 16b-3
Macroaxis News
over a week ago at investing.com         
Biodesixs chief development officer sells shares for 595
Investing News at Macroaxis
over a week ago at investing.com         
Biodesix CFO Robin Harper Cowie sells 1,355 in stock
Investing News at Macroaxis
over a week ago at investing.com         
Biodesix chief commercial officer sells shares worth 644
Investing News at Macroaxis
over a week ago at investing.com         
Biodesix CEO Scott Hutton sells 5,219 in stock
Investing News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Biodesix that are available to investors today. That information is available publicly through Biodesix media outlets and privately through word of mouth or via Biodesix internal channels. However, regardless of the origin, that massive amount of Biodesix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biodesix news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biodesix relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biodesix's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biodesix alpha.

Biodesix Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 434 shares by Gary Pestano of Biodesix at 1.4795 subject to Rule 16b-3
09/04/2024
2
Disposition of 327 shares by Robin Cowie of Biodesix subject to Rule 16b-3
10/11/2024
3
Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024
10/18/2024
4
Acquisition by Scott Hutton of 180926 shares of Biodesix at 1.46 subject to Rule 16b-3
10/22/2024
5
Acquisition by Vazquez Chris of tradable shares of Biodesix subject to Rule 16b-3
10/25/2024
6
Acquisition by Kennedy Lawrence T. Jr of 51200 shares of Biodesix at 1.365 subject to Rule 16b-3
11/05/2024
7
Biodesix director Matthew Strobeck acquires 55,915 in stock
11/06/2024
8
Biodesix, Inc. Shares Bought by Perkins Capital Management Inc.
11/07/2024
9
Disposition of 500 shares by Robin Cowie of Biodesix at 1.3909 subject to Rule 16b-3
11/11/2024
10
Disposition of 471 shares by Robin Cowie of Biodesix at 1.4008 subject to Rule 16b-3
11/12/2024
11
Biodesix chief accounting officer sells 283 in stock
11/13/2024
12
Disposition of tradable shares by Gary Pestano of Biodesix subject to Rule 16b-3
11/18/2024
13
Acquisition by Kennedy Lawrence T. Jr of 35000 shares of Biodesix at 1.1589 subject to Rule 16b-3
11/21/2024

Additional Tools for Biodesix Stock Analysis

When running Biodesix's price analysis, check to measure Biodesix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodesix is operating at the current time. Most of Biodesix's value examination focuses on studying past and present price action to predict the probability of Biodesix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodesix's price. Additionally, you may evaluate how the addition of Biodesix to your portfolios can decrease your overall portfolio volatility.